Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
Status:
Terminated
Trial end date:
2018-08-20
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if oral everolimus is tolerable and effective in
the treatment of sporadic Angiomyolipomas (AMLs). AMLs are the most common non-cancerous
tumor of the kidney. They are composed of blood vessels, muscle cells and fat
cells.Everolimus is already an approved drug for several other diseases like kidney cancer,
but is being studied now specifically to see if it is helpful for people with AML.